Personal tools

Program

The program of the symposium

LKI Symposium “Tumor Immunology & Immunotherapy: harnessing the immune system to fight cancer” Leuven, Campus Gasthuisberg, Onderwijs en Navorsing II 12--14 September 2016

Download PDF

Day 1
12:00-13:30 Registration and coffee
13:30-13:40 Welcome and opening by
  Prof. Dr. Wim Robberecht, Vice-rector of KU Leuven and Chairman of the Board University Hospitals Leuven
  Prof. Dr. Jo Van Lint, Coordinator for Translational Cancer Research of the Leuven Cancer Institute
 
Session 1: Defining tumor antigens and immunogenicity (Chair: Prof. Karim Vermaelen, University of Ghent)
13:40-14:20 Prof. Dr. Pierre Coulie (UCL, Woluwe) "Tumor heterogeneity: a problem for cancer immunotherapy"
14:20-15:00 Poster blitz sessions (20 posters, 2-min each)[posters nr 1-20]
15:00-15:40 Prof Dr. Zlatko Trajanoski (Biocenter, Innsbruck) “Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade”
15:40-16:00 REFRESHMENTS
 
Session 2: Vaccine based immunotherapy (Chair: Prof. Viggo Van Tendeloo, University of Antwerp)
16:00-16:40 Prof. Dr. Carl Figdor (Radboud University Medical Center, Nijmegen, NL) “Dendritic cell based immunotherapy”
16:40-17:00 Selected oral communication
17:00-17:40 Prof. Dr. Zwi Berneman (University of Antwerp) “Dendritic cell vaccination in leukemia and solid tumors”
17:40-17:50 concluding remarks day 1
19:00-22:00 Dinner (speakers)

 

Day 2
08:30-08:50 "Meet the expert" breakfast with Prof. Carl Figdor, Prof. Zlatko Trajanoski, and Prof. Zwi Berneman
08:00-08:50 Arrival
08:50-09:00 Welcome
 
Session 3: Immune checkpoint blockade and immunostimulatory antibodies (Chair: Prof Zwi Berneman, University of Antwerp)
09:00-09:40 Prof. Dr. Karim Vermaelen (University of Ghent) “The “Jekyll and Hyde” of the tumor-associated dendritic cell system in lung cancer and its potential clinical relevance”
09:40-10:20 Poster blitz sessions (20 posters, 2-min each)[posters nr 21-41]
10:20-11:00 Prof Dr Aurelien Marabelle (Institut Gustave Roussy, Paris) “How can we overcome resistance to immune checkpoint blockade?”
11:00-11:20 REFRESHMENTS
 
Session 4: Tumor targeting antibodies (Chair: Prof. Patrick Neven, KU Leuven)
11:20-12:00 Prof. Dr. Jan van de Winkel (CEO of Genmab, Utercht, NL) “Antibodies for the treatment of hematological malignancies”
12:00-12:20 Selected oral communication
12:20-13:00 Prof Dr Özlem Türeci (Ganymed, Mainz) “Developing immune effector mobilizing antibodies in nonhematological cancers"
13:00-14:00 LUNCH-poster viewing-meet the expert lunch
13:00-14:00 "Meet the expert” lunch with Prof. Pierre Coulie, Dr Jeroen Lammerts van Bueren and Prof, Karim Vermaelen
 
Session 5: Adoptive T-cell therapy(Chair: Prof. Dr. Steven Devleeschouwer, KU Leuven)
14:00-14:40 Prof. Dr. Viggo Van Tendeloo (University of Antwerp) “The ins and outs of generating redirected T cells using T cell receptor gene transfer for cancer immunotherapy"
14:40-15:00 Selected oral commnunication
15:00-15:40 Prof. Dr. Reno Debets (Erasmus University, Rotterdam, NL) “T Cell Receptor-Engineered T Cells to Treat Solid Tumors”
15:40-16:00 REFRESHMENTS
   
Session 6: Gut microbiota, immunity and cancer(Chair: Prof. Geert Van Loo, IRC, VIB-Gent)
16:00-16:40 Dr Maria Paula Roberti (Institut Hustave Roussy, Paris) “Gut microbiota and cancer therapeutics”
16:40-17:00 Selected oral communication
17:00-17:20 Best poster awards and concluding remarks day 2
19:00-22:00 Dinner (conference)

 

Day 3
08:30-08:50 Arrival
08:00-08:50 "Meet the expert" breakfast with Prof. François Ghiringhelli and Prof. Len Seymour
08:50-09:00 Welcome
 
Session 7: Inflammation, tumor microenvironment and immune escape (Chair: Prof. Dr. Patrizia Agostinis KU,Leuven)
09:00-09:40 Prof. Dr. Massimilano Mazzone (VIB and Vesalius Research Center, KU,Leuven) “Macrophage entry in hypoxia: Implications for cancer immunosuppression”
09:40-10:00 Selected oral communication
10:00-10:40 Prof. Dr. François Ghiringhelli (INSERM, Dijon) “Chemotherapy and anticancer immune responses"
10:40-11:00 REFRESHMENTS
 
Session 8: New approaches to cancer immunotherapy (Chair: Prof. Bart Vandekerckhove, University of Ghent)
11:00-11:40 Dr Abhishek Garg (KU Leuven) “Cancer cell death "with a twist": Towards next-generation dendritic cell immunotherapy”
11:40-12:00 Selected oral communication
12:00-12:40 Prof. Dr. Len Seymour (University of Oxford, UK) “Targeting immunotherapy to tumours using oncolytic viruses”
12:40-13:00 Concluding remarks
13:00-14:00 LUNCH - poster viewing – meet the expert lunch
13:00-14:00 "Meet the expert” lunch with Prof. Reno Debets, Dr Maria Paula Roberti, Prof. Max Mazzone, Prof. Viggo Van Tendeloo and Dr Abhishek Garg

 

List of poster abstracts (listed alphabetically by family name of presenting author)

Please mount your poster on the board corresponding to your poster number in the poster hall at floor 6.
Posters 1-­‐20 will be presented in 2 minute blitz slide sessions on 12 September from 14:20-­‐15:00
Posters 21-­‐41 will be presented in 2 minute blitz slide sessions on 13 September from 09:40-­‐10:20

1 Ana Rita Antunes, Karen De Vlaminck, Jo Van Ginderachter, KiavashMovahedi Dissecting the heterogeneity and functions of tumor-associated macrophages in glioblastoma
2 Assabban Assiya, Andrianne Mathieu, Blackshear Perry J., Van Maele Laurye, Goriely Stanislas Tristetraprolin expression by keratinocytes plays a key role in the control of inflammation and carcinogenesis.
3 Bala Attili, Petya Georgieva, Dieter Ory, Thomas Mathivet, Joost Dejaegher, Steven De Vleeschouwer, Guy Bormans In Vitro Positron emission tomography imaging of Translocator protein (TSPO) in brain tumors
4 Baert T, Garg AD, Vindevogel E, Van Hoylandt A, Verbist G, Agonistinis P, Vergote I, Coosemans A In vitro generation of murine dendritic cells for cancer immunotherapy: An optimized protocol
5 Baert T, Mathivet T, Van Hoylandt A, Vergote I, Coosemans A Tumor-associated macrophage phenotype makes low grade ovarian cancer a possible target for immunotherapy
6 Jochen Belmans, Matthias Van Woensel, Brecht Creyns, Jean-Pierre Locquet, Dominique Bullens, Stefaan Van Gool Immunotherapy with subcutaneous autologous tumor lysate increases glioblastoma survival in temozolomide treated mice
7 Mohammed Benkheil, Sam Noppen, Jan Paeshuyse, Johan Neyts, Sandra Liekens Hepatitis C Virus induced EGFR activation: role in liver pathogenesis
8 Bonelli Stefano1, Laoui Damya, Keirsse Jiri, Schoonooghe Steve, Van Ginderachter Jo Targeting Neuropilin-­1 through single­domain antibodies: a novel strategy to tackle tumor-­associated macrophages
9 Diana Campillo-Davo, Fumihiro Fujiki, Johan Van den Bergh, Evelien Smits, Haruo Sugiyama, Viggo F.I. Van Tendeloo, Zwi Berneman Electroporation of Dicer-­substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms’ tumor 1 (WT1)-­specific TCR-­ redirected cytotoxic T Cells
10 Flora D’Anna, Hui Zhao, Rebecca V. Berrens, Liesbeth Minnoye, Savvas N. Savvides, Wolf Reik, Bernard Thienpont, Diether Lambrechts Hypoxia, DNA methylation and retrotransposons: an opportunity for cancer immunotherapy?
11 Lutz Nuhn, Sunil A. David, Stefaan De Kker, and Bruno G. De Geest Biomimetic nanoparticles for lymph node focused immune activation
12 Yannick De Vlaeminck, Cleo Goyvaerts, Carlo Heirman, Kris Thielemans, Jo Van Ginderachter and Karine Breckpot Dissecting the biology of tumor­associated macrophages using lentiviral vectors and nanobodies
13 Joost Dejaegher, MD – Ellen Vercalsteren – Louis Boon, PhD - Steven De Vleeschouwer, MD, PhD PD-­1 expression and therapeutic blockade in the GL261 murine malignant glioma model.
14 Isabelle Dierckx de Casterlé, Omer Rutgeerts, Sabien Fevery, Stefaan Van Gool, Mark Waer, An D. Billiau, Ben Sprangers Immunotherapy for high-­risk neuroblastoma: allogeneic stem cell transplantation and recipient leucocyte infusion.
15 Monica Gordon-­Alonso, Claude Wildmann, Thibault Hirsch and Pierre van der Bruggen Tumor microenvironment restrains cytokine diffusion: a novel mechanism for tumor immune evasion
16 Chunyan Gu-­Trantien, Edoardo Migliori, Laurence Buisseret, Alexandre de Wind, Sylvain Brohée, Soizic Garaud, Luan Dang, Jean-Nicolas Lodewyckx, Céline Naveaux, Hugues Duvillier, Stanislas Goriely, Denis Larsimont and Karen Willard-­Gallo Tfhx13 cells link immune suppression and adaptive memory in human breast cancer
17 Marc Hennequart, Luc Pilotte, Stefania Cane, Vincent Stroobant, Etienne De Plaen, Benoit Van den Eynde Cyclooxygenase-­2 triggers constitutive tryptophan catabolism in human tumors and favors immune evasion
18 Jacobs Julie, Deschoolmeester Vanessa, Zwaenepoel Karen1, Hermans Christophe, Rolfo Christian, Lardon Filip, Siozopoulou Vasiliki, Smits Evelien, Pauwels Patrick CD70-­positive colorectal cancer associated fibroblasts: prognostic factor and immune escape mechanism
19 Eva Van Overmeire, Evangelia Bolli, Mate Kiss, Andrea Casazza, , Jiri Keirsse, Imane Song, Isabelle Houbracken, Inge Vercauteren, Yvon Elkrim, Frank Tacke, Louis Boon, Massimiliano Mazzone, Sofie Struyf, Damya Laoui and Jo A. Van Ginderachter The CCL8/CCR8 axis maintains an immunosuppressive tumor microenvironment
20 Klaessens S, De Plaen E, Stroobant V1 and Van den Eynde B. Characterization of a feedback loop that regulates the activity of TDO, an enzyme involved in tumor immune escape.
21 S.K. Larsen, D. Schröder (MD), J. Carrasco (MD, PhD), O. Bricard, G. Hames, N. Remy, Missault Kevin, J.-­L. Canon (MD), P Vannuffel (PhD), C. Galant (MD, PhD), M. Berlière (MD, PhD), P. G. Coulie (MD, PhD) Determining the frequency and clonality of known tumor-specific cytolytic T cells in the blood of a patient with primary breast carcinoma
22 Heleen Dewitte, Sandra Van Lint, Katrien Vanderperren, Emmelie Stock Stefaan C. De Smedt, Karine Breckpot and Ine Lentacker Microbubbles as magic bullets in cancer immunotherapy
23 Stéphanie Liénart, Julia Cuende, Olivier Dedobbeleer, Bas van der Woning, Gitte De Boeck, Julie Stockis, Caroline Huygens, Didier Colau, Joan Somja, Philippe Delvenne, Muriel Hannon, Frédéric Baron, Laure Dumoutier, Jean-­‐Christophe Renauld, Hans De Haard, Michael Saunders, Pierre G. Coulie and Sophie Lucas Monoclonal antibodies against GARP/TGF-­1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
24 Alessandra Lopes, Kevin Vanvarenberg, Véronique Préat and Gaëlle Vandermeulen. Optimization of DNA cancer vaccine increases antigen production and delays P815 mastocytoma tumor growth
25 Ken Maes, Sarah Melhaoui, Brenda De Keersmaecker, Karine Breckpot, Kim De Veirman, Eline Menu, Elke De Bruyne and Karin Vanderkerken Decitabine and quisinostat exert immunogenic effects in the 5T33 murine multiple myeloma model.
26 Elly Marcq, Vasiliki Siozopoulou, Jorrit De Waele, Jonas Van Audenaerde, Karen Zwaenepoel, Eva Santermans, Niel Hens, Patrick Pauwels, Jan P van Meerbeeck, Evelien LJ Smits Characterization of the tumor microenvironment and investigation of immune checkpoint expression in malignant pleural mesothelioma
27 B. Mertens, TC. Nogueira, D. Topalis, R. Stranska, G. Andrei, R. Snoeck Rega Institute for medical research, KU Leuven, Leuven Belgium Addition of an adjuvant to cidofovir treatment of primary human papillomavirus positive tumor influences untreated secondary tumor in mice
28 Vladan Milosevic, Joanna Kopecka, Iris C. Salaroglio, Silvia Novello, Luisella Righi, Giorgio Scagliotti, Chiara Riganti Malignant pleural mesothelioma creates an immunosuppressive microenvironment due to the presence of cancer stem cells
29 Erminia Romano, Abhishek D Garg, Hannelore Maes, Aleksandra Dudek-­Peric, Hannelie Korf, Peter De Witte and Patrizia Agostinis BNIP3: a key modulator of the melanoma-­ macrophages interface
30 Nicole Rufo, Abhishek D. Garg, Thomas Sauter, Jean-­Christophe Marine, Patrizia Agostinis Systems Biology of Immunogenic Cell Death (ICD) in Melanoma
31 P. Ruytinx, N. Berghmans, N. Pörtner, L. Vanbrabant, S. Noppen, S. Liekens, I. Ronsse, J. Van Damme, S. Struyf Angiostatic activity of two natural CXCL4L1 isoforms
32 Marco BE Schaaf, Hannelore Maes, Sampad Jana, Joice Thomas, Kasper MA Rouschop, Wim Dehaen, Patrizia Agostinis Derivatives of chloroquine to improve anticancer therapy
33 Karolin Schneider, Vanesa Bol, Pierre Coulie, Vincent Grégoire Radiation induced immunogenic cell death signals in human HPV-­positive and HPV-­negative HNSCC cell lines
34 Ariane Scoumanne, Virginie Rabolli, Murielle Martini, Marie-Claire Letellier, Stefano Crosignani, Christophe Quéva, Michel Detheux, Jakub M Swiercz, Sandra Cauwenberghs Development and validation of a phenotypic screening platform for the identification of novel immuno-oncology targets
35 Trompet Erika, Tousseyn Thomas, Snoeck Robert, Andrei Graciela Organotypic epithelial raft cultures for the ex vivo study of lymphoproliferative disorders
36 Heleen H. Van Acker, Ottavio Beretta, Sébastien Anguille, Lien De Caluwé, Angela Papagna, Johan M. Van den Bergh, Yannick Willemen, Herman Goossens, Zwi N. Berneman, Viggo F. Van Tendeloo, Evelien L. Smits, Maria Foti, Eva Lion Superior cytolytic immune effector cell recruitment by interleukin-­15 dendritic cells
37 Van den Bergh JMJ, Willemen Y, Lion E, De Reu H, Berneman ZN, Van Tendeloo VFI, Smits ELJM, Transpresentation of interleukin-­15 by IL-­15/IL-­15R mRNA-­engineered human dendritic cells boosts antitumoral natural killer cell activity
38 Damya Laoui, Jiri Keirsse, Yannick Morias, Patrick De Baetselier, Massimiliano Mazzone, Martin Guilliams, Jo A. Van Ginderachter The tumor microenvironment harbors ontogenically distinct dendritic cell populations with opposing effects on tumor immunity
39 Van Hoeck J., Wayteck L., Dewitte H., Xiong R., Breckpot K., Braeckmans K., De Smedt S.C., Raemdonck K. Hitchhiking nanoparticles: exploring novel siRNA delivery approaches on cytotoxic T cells
40 Matthias Van Woensel & Thomas Mathivet, Nathalie Wauthoz, Rémi Rosière, Véronique Mathieu, Robert Kiss, Florence Lefranc, Louis Boon, Jochen Belmans, Stefaan W. Van Gool, Holger Gerhardt, Karim Amighi, Steven De Vleeschouwer Sensitization of glioblastoma tumor micro-­ environment to chemo-­ and immunotherapy by Galectin-­1 intranasal knock-­down strategy
41 Mathias Wenes, Min Shang, Mario Di Matteo, Jermaine Goveia, Rosa Martín-­‐ Pérez, Jens Serneels, Hans Prenen, Bart Ghesquière, Peter Carmeliet, Massimiliano Mazzone Macrophage metabolism controls tumor blood vessel morphogenesis and metastasis

 

  • Last modified 07-09-2016